Tempus AI, Inc. (TEM)
NASDAQ • Healthcare
September 10, 2026 at 19:44 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Tempus AI, Inc. keeps $1 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 3
in 54 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Tempus AI beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 30, 2026, as revenue rose 22% to about $382.5 million from $314.6 million a year earlier and edged the $379.7 million consensus by 0.7%, while adjusted EPS of -$0.04 compared with a -$0.14 estimate and improved from -$0.22 a year ago. Gross profit reached about $274.3 million, with gross margin holding near 72%, but operating income was negative $75.9 million and operating margin was about -20%. Operating cash flow came in at $73.3 million. For the next period, consensus calls for adjusted EPS of -$0.09 on revenue of $413.5 million.
About Tempus AI, Inc.
Tempus AI, Inc. (NASDAQ: TEM) provides data-driven diagnostics and software for cancer care and drug development within healthcare information services, combining laboratory testing with clinical data tools. The company generated $1.3 billion in FY2025 revenue and sells its services to care providers, life sciences companies, and research users.
Today's Snapshot
TEM is trading 3.6% below yesterday's close, in line with a weaker sector. Tempus AI won up to $9.5 million from ARPA-H, a federal health agency, to develop AI for heart care.
Trading Volume
Below 10d avg (6.0M)
4.4M
vs S&P 500 Today
Strong Underperformance
-3.00%
Updated: September 10, 2026 at 19:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$55.87 - $62.56Sell
- RSI (14)47.87Neutral
- Stochastic %K (14, 3, 3)22.19Neutral
- MACD Level (12, 26)2.25Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.